Cellular Immunology Laboratory, Hôpital E. Herriot, Hospices Civils de Lyon, Pavillon E, 5 place d'Arsonval, 69437 Lyon Cedex 03, France.
Expert Rev Anti Infect Ther. 2010 Oct;8(10):1109-12. doi: 10.1586/eri.10.107.
Sepsis still constitutes a public health challenge worldwide since its incidence constantly increases over time but its related mortality remains more or less constant. There is thus an unquestionable and urgent need to develop innovative and efficacious therapies for the treatment of this deadly disease. In this study, the authors propose that injection of mesenchymal stem cells rescues mice from death after septic shock owing to their potent immunosuppressive and anti-inflammatory properties. The authors conclude that immunomodulatory cell therapy may represent an effective treatment for sepsis. While the potential therapeutic value of these cells is not to be challenged, considering the present lack of convincing data about mesenchymal stem cell use in sepsis, we do not believe that they constitute the next topical clinical trial in the field. Rather, recent evidence indicates that most septic patients actually present with profound immune alterations suggesting that anti-inflammatory approaches could deleteriously amplify this state. Therefore, in this article, we propose hypotheses explaining why the future of clinical trials in sepsis immunology will likely rely on stimulating immune functions for rebalancing immune homeostasis.
败血症仍然是一个全球性的公共卫生挑战，因为它的发病率随着时间的推移不断增加，但其相关死亡率却或多或少保持不变。因此，迫切需要开发创新和有效的治疗方法来治疗这种致命疾病。在这项研究中，作者提出，间充质干细胞的注射可以挽救败血症性休克后小鼠的死亡，因为它们具有强大的免疫抑制和抗炎特性。作者得出结论，免疫调节细胞疗法可能是败血症的一种有效治疗方法。虽然这些细胞的潜在治疗价值不容置疑，但考虑到目前关于间充质干细胞在败血症中应用的令人信服的数据缺乏，我们认为它们并不是该领域下一个有前景的临床试验。相反，最近的证据表明，大多数败血症患者实际上存在严重的免疫改变，这表明抗炎方法可能会有害地放大这种状态。因此，在本文中，我们提出了一些假设，解释了为什么败血症免疫学临床试验的未来可能依赖于刺激免疫功能以重新平衡免疫稳态。
